{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-199425","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.036372+00:00","generated_at":"2026-05-31T09:44:36.776602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"UroGen ahead of schedule completing UGN-102 NDA; Q2 revenue $21.8M, net loss $33.4M","bullets":["UGN-102 NDA completion imminent; potential FDA decision as early as Q1 2025 assuming priority review.","Q2 JELMYTO net revenue $21.8M (+3% YoY); full-year revenue expected at lower end of guidance range.","Q2 net loss $33.4M ($0.91/share) vs $24.1M ($1.03/share) in Q2 2023; operating loss $25.8M.","Cash & marketable securities $241.3M at June 30; June public offering raised $107.5M gross.","Full-year operating expenses expected at higher end of guidance; R&D $15.4M, SG&A $30.1M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-199425","json":"https://secwatch.observer/filing/0001193125-24-199425.json","markdown":"https://secwatch.observer/filing/0001193125-24-199425.md","text":"https://secwatch.observer/filing/0001193125-24-199425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524199425/0001193125-24-199425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524199425/d865545d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:36.776602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}